Profound Medical Secures $36M to Advance AI-Powered Prostate Treatment

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a commercial-stage medical device company, has successfully closed a registered direct offering of 5,142,870 common shares at $7.00 per share, generating approximately $36 million in gross proceeds. This strategic equity investment, led by healthcare-dedicated investors and existing shareholders, was facilitated by Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC, which acted as the exclusive placement agent. The company plans to allocate the net proceeds toward expanding sales and marketing activities, bolstering working capital, advancing research and development, pursuing strategic transactions, and covering general corporate purposes. This financial boost is poised to accelerate Profound's mission of transforming prostate disease treatment through innovative, non-invasive technologies.

At the heart of Profound's portfolio is the TULSA-PRO® system, an AI-powered, MRI-guided therapeutic platform that offers an incision- and radiation-free ablation procedure for prostate conditions. The TULSA Procedure™ combines real-time MRI imaging, AI-enhanced planning, robotically-driven transurethral ultrasound, and closed-loop temperature feedback to precisely target diseased tissue while preserving urinary continence and sexual function. Approved by regulatory bodies including the FDA, Health Canada, and CE marked, this "one-and-done" treatment addresses a broad spectrum of prostate diseases, from low- to high-risk cancer and benign prostatic hyperplasia (BPH), with minimal recovery time and no hospital stay required. Additionally, Profound markets the Sonalleve® platform, CE marked for treating uterine fibroids, adenomyosis, and other conditions, with FDA approval for osteoid osteoma and ongoing exploration into abdominal cancer ablation.

This news release was disseminated through the InvestorWire platform, part of the Dynamic Brand Portfolio at IBN, which specializes in wire-grade press release syndication and corporate communications solutions. For more details, readers can visit the full press release via the provided link. Profound's advancements represent a significant leap in medical technology, potentially reducing the physical and emotional burden of traditional prostate treatments. The company's commitment to innovation, supported by this recent funding, underscores its role in shaping the future of minimally invasive therapies, offering hope to patients worldwide seeking safer, more effective alternatives for managing prostate and other diseases.